NEW YORK, NY / ACCESSWIRE / July 21, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Mirati Therapeutics, Inc. ("Mirati" or "the Company") (NASDAQ:MRTX). Investors who purchased Mirati securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Mirati has violated federal securities laws.
Investigation Details:
On July 21, 2023, Mirati issued a press release "announc[ing] the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on the Conditional Marketing Authorisation Application (MAA) for KRAZATI® (adagrasib) for treatment of patients with KRASG12C -mutated advanced non-small cell lung cancer (NSCLC)." Specifically, Mirati reported that "CHMP states that KRAZATI has a positive risk-benefit profile, however, does not fulfill certain requirements for a Conditional Marketing Authorisation." On this news, Mirati's stock price fell sharply during intraday trading on July 21, 2023.
What's Next?
If you are aware of any facts relating to this investigation or purchasedMirati securities, you can assist this investigation. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Why Bronstein, Gewirtz & Grossman:
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Bronstein, Gewirtz and Grossman, LLC